Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)

CNY 25.56

(1.43%)

Market Cap (In CNY)

3.99 Billion

Revenue (In CNY)

920.01 Million

Net Income (In CNY)

150.45 Million

Avg. Volume

1.22 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
20.07-39.05
PE
-
EPS
-
Beta Value
0.428
ISIN
CNE1000036K3
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jianhua Liu
Employee Count
-
Website
https://www.konruns.cn
Ipo Date
2018-09-03
Details
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs in China. The company offers Su Ling product in the hemagglutinin preparation market used to reduce bleeding during surgery and control postoperative surgery. It also engages in the development of drug candidates, including CX1026, CX1003, and KC1036. The company was founded in 2003 and is headquartered in Beijing, China.